Dr. Justin Schweitzer's 2024 AAOpt talk will cover the latest advancements in ocular drug delivery, including topical, implant, and contact lens-based methods that can improve patient quality of life, adherence, and financial burden.
Optometrists are constantly seeking new and innovative ways to better serve patients. One area that has seen significant advancements in recent years is ocular drug delivery. At the upcoming 2024 American Academy of Optometry meeting in Indianapolis, Justin Schweitzer, OD, FAAO, and Walter Whitley, OD, MBA, FAAO, will be presenting a 50-minute session that delves into the latest developments in this critical field.
According to Schweitzer, a self-proclaimed "glaucoma guy," the session will cover a wide range of ocular drug delivery methods, from topical drops to implants placed directly within the eye. "We're excited to really dive into the different avenues of ocular drug delivery," he explains. "Whether it's from a glaucoma standpoint, with new implants being placed inside the eye, or advancements in retinal drug delivery, there's a lot of exciting progress happening." One area of particular interest is the role optometrists can play in these new drug delivery techniques and devices. "We want to discuss how optometry can be involved in these procedures and help our patients access these innovative solutions," Schweitzer says.
This is crucial, as many of these advancements have the potential to significantly improve patient quality of life and financial burden. "A big focus for us will be on how these new drug delivery methods can help patients who are struggling with adherence or the cost of their medications," Schweitzer explains. "If we can find ways to reduce the number of drops they need to take or provide longer-lasting solutions, it can make a real difference in their daily lives." The session will also touch on emerging technologies, such as the use of contact lenses for drug delivery. "There's some really interesting work being done with contact lenses that can deliver medications for glaucoma, dry eye, and even allergies," Schweitzer notes. "We'll be sure to give a brief overview of these advancements and what they could mean for our patients in the near future."